Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 33 for “"tumor antigens"”.

  1. Tumor Antigens Revealed by Exome Seqeuncing Drive Editing of Tumor Immunogenicity

    … immunity cannot only function as an extrinsic tumor suppressor, but also shape tumor immunogenicity. These observations led to the development of the cancer immunoediting hypothesis that stresses the dual host-protective and tumor-sculpting actions of immunity on developing cancers. We …

    wustl Repository record for Tumor Antigens Revealed by Exome Seqeuncing Drive Editing of Tumor Immunogenicity (opens in a new tab)

  2. Cross-Presentation Is A Source of Tumor Antigens For Multiple Myeloma Immunotherapy

    … cross-presentation as a mechanism by which solid tumors present exogenous antigens. We therefore hypothesized that multiple myeloma would be capable of cross-presentation as these cells are derived from B cells, known APCs. We explored the capacity of multiple myeloma to cross-present PR1, a human …

    uthsc Repository record for Cross-Presentation Is A Source of Tumor Antigens For Multiple Myeloma Immunotherapy (opens in a new tab)

  3. Model systems for the retargeting of T cell-mediated immunity to tumor antigens

    … are involved in the response against foreign antigens. Specificity of B cells is determined by antibodies while the specificity of T cells is determined by similar proteins called T-cell receptors. One function of T cells is surveillance against tumor cells. Progressing tumors have escaped T …

    uiuc Repository record for Model systems for the retargeting of T cell-mediated immunity to tumor antigens (opens in a new tab)

  4. The Role of Anti-Viral Immune Response on the Therapeutic Efficacy of Oncolytic Virotherapy for High-Grade Gliomas

    … replicating in cancer cells and inducing anti-tumor immunity. Among these viruses, the oncolytic adenovirus Delta-24-RGD has shown safety and efficacy in clinical trials for high-grade gliomas. Strategies to improve the efficacy of oncolytic virotherapy have aimed to heighten the immunogenicity …

    uthsc Repository record for The Role of Anti-Viral Immune Response on the Therapeutic Efficacy of Oncolytic Virotherapy for High-Grade Gliomas (opens in a new tab)

  5. Studies on the synergistic protective activity of cancer antigens associated to engineered bacterial Outer Membrane Vesicles

    … such complexes, which carry TEX- associated tumor antigens and OMV-associated immune-stimulatory molecules, elicit anti-tumor immune responses in vivo. Results Immunization with OMVs engineered with two B cell epitopes (EGFRvIII and D8-mFAT1) induced tumor growth inhibition after mouse …

    trento Repository record for Studies on the synergistic protective activity of cancer antigens associated to engineered bacterial Outer Membrane Vesicles (opens in a new tab)

  6. Antibody engineering for cancer therapy

    Antibodies targeting various tumor-associated antigens have been developed successfully to treat cancer. In this Thesis, novel antibodies and antibody-conjugate against two tumor antigens, AF-20 antigen and human aspartyl (asparaginyl) [beta]- hydroxylase (HAAH), were developed. Previously, these …

    mit Repository record for Antibody engineering for cancer therapy (opens in a new tab)

  7. The Use of High-Affinity T Cell Receptors to Study Specificity in the 2C T Cell System

    … the detection and diagnosis of specific virus or tumor antigens (peptide-MHC) on the cell surface. In addition, the TCRs would provide a useful probe for tracking the processing and presentation of specific antigens. Chapter 6 discusses the development of soluble single-chain TCRs with enhanced …

    uiuc Repository record for The Use of High-Affinity T Cell Receptors to Study Specificity in the 2C T Cell System (opens in a new tab)

  8. Engineering protein-based modulators of allergic, temporal, and checkpoint blockade anti-cancer immunity

    … designing IgE class antibodies against two mouse tumor antigens and comparing them with traditional IgG antibodies. These IgE antibodies elicited modest or no tumor control, and limited efficacy could be due to fast pharmacokinetic clearance, absence of human-like allergic effector cells in mice, …

    mit Repository record for Engineering protein-based modulators of allergic, temporal, and checkpoint blockade anti-cancer immunity (opens in a new tab)

  9. Financial viability and technical evaluation of dendritic cell-carrying "vaccination nodes" for immunotherapy

    … the immune system to reject and destroy tumor cells. Despite the amount of ongoing intensive research to prevent cancer, tumor cells continue to evade immune responses. Currently, dendritic cell vaccines are in development, in which autologous antigen-loaded dendritic cells are injected …

    mit Repository record for Financial viability and technical evaluation of dendritic cell-carrying "vaccination nodes" for immunotherapy (opens in a new tab)

  10. Investigating immune surveillance, tolerance, and therapy in cancer

    … human disease to study T cell responses to tumor antigens and to test immune therapeutic strategies. Current model systems largely relied on chemically-induced and spontaneous tumors in immunodeficient mice or on transplanted tumors. Such systems are limited because they fail to reproduce …

    mit Repository record for Investigating immune surveillance, tolerance, and therapy in cancer (opens in a new tab)

  11. Locally Administered Particle-Anchored Cytokines Safely Enhance Cancer Immunotherapy

    … been proposed as a powerful approach to curing tumors, based on the natural function of the immune system in protecting its host with specificity, thus holding the potential for developing long-term memory that prevents tumor recurrence. However, the immunosuppressive feature of the tumor

    vt Repository record for Locally Administered Particle-Anchored Cytokines Safely Enhance Cancer Immunotherapy (opens in a new tab)

  12. Epiregulin as a Novel Target for Antibody-Drug Conjugate Development for the Treatment of Colorectal Cancer

    … a potent cytotoxic payload to selectively target tumor antigens highly expressed on the cell surface. ADC development has been limited in colorectal cancer (CRC) by the lack of novel and effective therapeutic targets. Epiregulin (EREG), is an epidermal growth factor receptor (EGFR) ligand that is …

    uthsc Repository record for Epiregulin as a Novel Target for Antibody-Drug Conjugate Development for the Treatment of Colorectal Cancer (opens in a new tab)

  13. Virus-Based Nanoparticles for Tumor Selective Targeting and Oncolysis

    … (NDV), an avian paramyxovirus, is naturally tumor-selective and inherently oncolytic. Our approach is to develop NDV-based nanoparticles (VBNP) for oncolytic virotherapy. VBNPs are non-infectious and non-replicating and are relatively safe. We obtained VBNPs by co-expressing matrix (M), …

    vt Repository record for Virus-Based Nanoparticles for Tumor Selective Targeting and Oncolysis (opens in a new tab)

  14. ROLE OF IL-10 PRODUCING EOMES+ TR1-LIKE CELLS IN MELANOMA

    … adaptive immune system’s ability to eradicate tumors are crucial for the development of effective cancer immunotherapies. In particular, the immunosuppressive functions of FOXP3+ T regulatory cells (Tregs) and EOMES+ type 1 regulatory T (Tr1) cells, which produce the anti-inflammatory cytokine …

    milano Repository record for ROLE OF IL-10 PRODUCING EOMES+ TR1-LIKE CELLS IN MELANOMA (opens in a new tab)

  15. Targeting Myeloid Protein Kinase C Signaling to Overcome Immune Suppression and Improve Immunotherapy in Cancer

    Checkpoint immunotherapy unleashes T cell antitumor potential which has revolutionized cancer treatment showing unprecedented long-term responses. However, most patients do not respond to immunotherapy which often correlates with a dysfunctional or immunosuppressive myeloid compartment. …

    tenn-hsc Repository record for Targeting Myeloid Protein Kinase C Signaling to Overcome Immune Suppression and Improve Immunotherapy in Cancer (opens in a new tab)

  16. Antigen-specific memory T cell distribution in non-lymphoid tissue

    … pathogens, particularly viruses, and tumor antigens. In the case of influenza, activated T cells migrate from the mediastinal (draining) lymph nodes to the lung where they perform their cytolytic function. After pathogen clearance, memory CD8+ T cells are generated, giving rise to …

    mit Repository record for Antigen-specific memory T cell distribution in non-lymphoid tissue (opens in a new tab)

  17. Engineering immunity : enhancing T Cell vaccines and combination immunotherapies for the treatment of cancer

    … response can be stimulated to elicit durable tumor regressions in metastatic cancer, but these dramatic responses are confined to a minority of patients¹-³. This outcome is likely due in part to the complex network of immunosuppressive pathways present in advanced tumors, which necessitates …

    mit Repository record for Engineering immunity : enhancing T Cell vaccines and combination immunotherapies for the treatment of cancer (opens in a new tab)

  18. Leveraging Innate Immune Sensors to Generate Durable Anti-Glioma Adaptive Immune Responses

    … aggressive primary brain malignancy harboring a tumor microenvironment that is mostly devoid of T cell effector infiltration but is dominated by immune suppressive microglia, macrophages, and myeloid-derived suppresser cells. These innate immune cells display impaired phagocytosis and antigen …

    uthsc Repository record for Leveraging Innate Immune Sensors to Generate Durable Anti-Glioma Adaptive Immune Responses (opens in a new tab)

  19. Defining The Cooperation Between Mhc-I and Mhc-Ii Neoantigen-Driven T Cell Responses to Develop Effective Personalized Immunotherapies

    … (α-PD-1)) enables durable T cell-dependent anti-tumor immunity in certain cancer patients. Since a subset of patients respond to ICT, this work aims at developing a more in-depth understanding of T-cell responses to MHC class I (MHC-I) and MHC class II (MHC-II) tumor antigens that are derived …

    uthsc Repository record for Defining The Cooperation Between Mhc-I and Mhc-Ii Neoantigen-Driven T Cell Responses to Develop Effective Personalized Immunotherapies (opens in a new tab)

Page 1 of 2